Currently, the checkpoints of programmed cell death protein 1(PD-1)/programmed cell death ligand 1(PDL1) and cytotoxic T lymphocyte antigen-4 (CTLA4) are widely exploited for cancer immunotherapy. The gene discussed is PDCD1; the disease is cancer.